ILiAD Biotechnologies

ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.

ActiveBioTechClinical TrialsHealth CarePharmaceutical

Website LinkedIn

Updated: Feb 17, 2026 ·

About

ILiAD Biotechnologies is a clinical-stage biotechnology company focused on addressing diseases caused by Bordetella Pertussis, commonly known as whooping cough. The company's primary mission is the prevention and treatment of this human infectious disease through innovative biotechnological approaches. It is actively engaged in the development of a next-generation pertussis vaccine.

Recent News & Mentions

Feb 10, 2026FundingILiAD Biotechnologies - Series D

Financial History

ILiAD Biotechnologies has raised $115.0M across 1 funding round. Most recently, it raised $115.0M Series D in February 2026.

Total Raised

$115.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Lead Investors	Other Investors
Feb 10, 2026	$115.0M Series D	RA Capital Management	AI Life Sciences Investments LLC, BNP Paribas Asset Management, Janus Henderson Investors

Financial History

ILiAD Biotechnologies has raised $115.0M across 1 funding round.

Total Raised

$115.0M

Valuation

N/A

Deep Dive

The company utilizes its proprietary B-Tech vector platform as a core component of its vaccine development strategy. This platform is designed to facilitate the creation of advanced vaccine candidates aimed at eradicating infectious diseases and improving public health outcomes. The focus on pertussis reflects a commitment to tackling a specific and persistent health challenge.

As a clinical-stage entity, ILiAD Biotechnologies is progressing its vaccine candidates through the necessary development phases. The company's work is centered on bringing effective new solutions to market for the prevention and treatment of pertussis, a disease that continues to pose a significant health threat globally.

ILiAD Biotechnologies was founded by Keith Rubin, M.D., who also serves as its Chief Executive Officer. Dr. Rubin is a member of the Executive Board, guiding the company's strategic direction and its efforts in vaccine innovation.

Sources

Frequently Asked Questions

What specific pathogen is the focus of ILiAD Biotechnologies' research?

ILiAD Biotechnologies is dedicated to the prevention and treatment of diseases caused by Bordetella Pertussis, the bacterium responsible for whooping cough.

What technological approach does ILiAD Biotechnologies employ for vaccine development?

The company utilizes a proprietary B-Tech vector platform to develop its next-generation vaccine candidates for infectious diseases.